Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTN vs IMMX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

IMMX Overall Winner 6-Pillar Tally: PTN 3 – 3 IMMX Matrix Metrics: PTN 2 – 8 IMMX

As of Nov 16, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Palatin Technologies, Inc. (PTN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas IMMX carries 53.1/100 (HOLD) at $7.48 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTN vs IMMX
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07
IMMX NASDAQ Head-to-Head Winner
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.48
-4.59% 1D
Market Cap $657.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.80β · 84% Vol
Unified Composite Score
53.1 / 100 HOLD
Tech 57.0 Fund 57.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $8.05 · SMA50: $9.69

6-Pillar Scorecard Institutional Category Breakdown (PTN 3 – 3 IMMX)

Columns: Metric · PTN · IMMX
1. Valuation Multiples PTN
Forward P/E 42.9x N/M
Trailing P/E 42.9x N/M
PEG Ratio 1.62x N/M
EV / Revenue 0.1x N/M
2. Growth & Scale IMMX
Revenue Growth (YoY) -80.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M N/A
Market Cap $11.1M $657.1M
3. Profitability & Quality IMMX
Gross Margin 6.2% N/A
Operating Margin -65.7% 0.0%
Net Profit Margin -63.5% 0.0%
Return on Equity (ROE) -877.5% -27.0%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$15M -$39M
Cash Flow Margin -113.6% N/A
Net Cash / Leverage $9.9M Net Cash $224M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMMX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 92.6% (17th %ile)
Put/Call OI Skew N/A 1.24x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity 71.9% of Rev ($9.5M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTN (2) vs IMMX (8)
Institutional Metric PTN IMMX Criterion Row Edge
Market Capitalization
Scale
$11.1M $657.1M Larger Scale IMMX
Trailing P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Forward P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Revenue Growth (YoY)
Growth
-80.1% +0.0% Higher Growth IMMX
Operating Margin (TTM)
Profitability
-65.7% 0.0% Higher Margin IMMX
Net Profit Margin
Profitability
-63.5% 0.0% Higher Margin IMMX
Return on Equity (ROE)
Capital Efficiency
-877.5% -27.0% Higher ROE IMMX
52-Week Range Position
Momentum
6% ($5–$31) 35% ($3–$15) Stronger Trend IMMX
Beta / 30D Volatility
Risk Regime
0.87β · 106% Vol 1.80β · 84% Vol Lower Realized Risk IMMX
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 53.1 / 100 (HOLD) Higher Composite IMMX
Trailing 12M Revenue (USD)
Operating Scale
$13M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
6.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.62x PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M ($9.9M Net Cash) -$39M ($224M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTN +8.01 pp
PTN: +1.74% · IMMX: -6.27%
3M Horizon IMMX +5.06 pp
PTN: -41.72% · IMMX: -36.66%
6M Horizon IMMX +43.01 pp
PTN: -59.81% · IMMX: -16.8%
1Y Horizon IMMX +150.49 pp
PTN: -43.29% · IMMX: +107.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PTN vs IMMX. Trailing 12-month operating profitability (PTN -65.7% vs IMMX 0.0%) and valuation multiples (PTN 42.9x vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PTN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin6.2%
Op. Margin-65.7%
ROE / Fwd P/E-877.5% · 42.9x
IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMMX BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 92.6%
IV Percentile 17th %ile
Put/Call OI Skew 1.24x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $657.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTN vs IMMX Key Questions & Quantitative Answers

As of Nov 16, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over Palatin Technologies, Inc. (PTN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas IMMX carries 53.1/100 (HOLD) at $7.48 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMMX leads the Growth & Scale pillar: PTN posts -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin), compared with IMMX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PTN generates $13M in USD-normalized revenue versus N/A for IMMX. In operating R&D and SG&A reinvestment, PTN deploys 71.9% of Rev ($9.5M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMX.

PTN screens cheaper on headline valuation multiples. PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin), whereas IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTN (-877.5% ROE) versus IMMX (-27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk). By comparison, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.24x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.80β · 84% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.